Same active ingredient, different delivery methods — two separate FDA-approved products.
Free consultation · No commitment · Results in weeks
From 2,000+ patients · Rybelsus vs Ozempic is already seeing results
Rybelsus vs Ozempic: both are FDA-approved GLP-1 medications for weight loss. Rybelsus (semaglutide) and Ozempic (semaglutide) differ in mechanism and clinical efficacy. Weight Method offers both from $199/month with virtual consultations and licensed providers.
Rybelsus and Ozempic are two separate FDA-approved products that both contain semaglutide from Novo Nordisk for type 2 diabetes, differing in delivery method. Ozempic is a once-weekly subcutaneous injection (0.25–2 mg) approved in 2017, while Rybelsus is a once-daily oral tablet (3–14 mg) approved in 2019. The oral form requires specific dosing conditions — taken on an empty stomach with a small amount of water, followed by a 30-minute fast — because oral semaglutide has lower bioavailability than the injectable form. Weight Method does not dispense or prescribe either brand-name product; our program provides compounded semaglutide through licensed providers and U.S.-licensed pharmacies. Which option is appropriate for you is a decision made by a licensed provider based on your individual medical profile.
Key Fact
Rybelsus (oral, up to 14 mg) and Ozempic (injectable, up to 2 mg) both contain semaglutide and are FDA-approved for type 2 diabetes. They differ in delivery route and dosing. Both are products of Novo Nordisk and are different from Weight Method's compounded program.
Source: FDA prescribing information (Rybelsus; Ozempic)
| Rybelsus | Ozempic | |
|---|---|---|
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Active Ingredient | semaglutide | semaglutide |
| FDA Indication | Type 2 diabetes | Type 2 diabetes |
| FDA Approval | 2019 | 2017 |
| Formulation | Oral tablet | Injectable pen |
| Frequency | Once daily | Once weekly |
| Available Doses | 3mg, 7mg, 14mg | 0.25mg, 0.5mg, 1mg, 2mg |
| Avg. Weight Loss | 5-10% | 10-15% |
| Our Price | $199/mo | $199/mo |
Rybelsus and Ozempic contain the same active ingredient and are both FDA-approved for type 2 diabetes; the difference is the delivery route (daily oral tablet vs. weekly injection) and the associated dosing and administration requirements. The mechanism class — GLP-1 receptor agonist — is the same. Which option is clinically appropriate for any individual depends on that person's medical history and preferences and is determined by a licensed provider. Both are different from Weight Method's compounded semaglutide, priced at $154/mo.
Rybelsus and Ozempic are distinct FDA-approved branded products from Novo Nordisk that differ in delivery route; neither is what Weight Method dispenses. The right option for an individual depends on that person's medical profile and preferences and is determined by a licensed provider. Weight Method's compounded semaglutide is available at $154/mo.
Answer a few quick questions to see if you qualify for GLP-1 medication.
Check EligibilityCompounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.

Compounded semaglutide. Once-weekly subcutaneous injection.

Compounded tirzepatide. Dual-action GLP-1/GIP, once-weekly subcutaneous injection.
Take our 2-minute quiz to see if you qualify for GLP-1 treatment.
Start QuizFree consultation. No commitment.